AstraZeneca to buy rare disease drugmaker Alexion in $39bn deal.
In: FRPT - Global Chemical Snapshot, 2020-12-22, S. 1
Online
Zeitungsartikel
Zugriff:
The article reports that pharmaceutical firm AstraZeneca will acquire Alexion in a cash and-shares deal. It mentions deal, is the largest in AstraZeneca's history, is expected to close in the third quarter of 2021 and AstraZeneca a foothold in the rare disease market, and business unit will be set up, led by Alexion management. Current Alexion chairman David Brennan knows AstraZeneca well and was its chief executive from 2006 to 2012.
Titel: |
AstraZeneca to buy rare disease drugmaker Alexion in $39bn deal.
|
---|---|
Link: | |
Zeitschrift: | FRPT - Global Chemical Snapshot, 2020-12-22, S. 1 |
Veröffentlichung: | 2020 |
Medientyp: | Zeitungsartikel |
Schlagwort: |
|
Sonstiges: |
|